Lactic acidosis often challenges the intensivist and is associated with a strikingly high mortality. Treatment involves discerning and correcting its underlying cause, ensuring adequate oxygen delivery to tissues, reducing oxygen demand through sedation and mechanical ventilation, and (most controversially) attempting to alkalinize the blood with IV sodium bicarbonate. Here we review the literature to answer the following questions: Is a low pH bad? Can sodium bicarbonate raise the pH \textit{in vivo}? Does increasing the blood pH with sodium bicarbonate have any salutary effects? Does sodium bicarbonate have negative side effects? We find that the oft-cited rationale for bicarbonate use, that it might ameliorate the hemodynamic depression of metabolic acidemia, has been disproved convincingly. Further, given the lack of evidence supporting its use, we cannot condone bicarbonate administration for patients with lactic acidosis, regardless of the degree of acidemia.

\textbf{Key words:} acid-base; acidosis; alkalinizing therapy; bicarbonate; lactic acidosis; sodium bicarbonate

\textbf{Abbreviations:} DCA = dichloroacetate; DKA = diabetic ketoacidosis; SID = strong ion difference

Lactic acidosis, defined as a lactate concentration $>5$ mmol/L and a pH $<7.35$, commonly complicates critical illness. Its causes are legion, including sepsis, cardiogenic shock, severe hypoxemia, hepatic failure, and intoxication. Many of these share reduced delivery of oxygen to cells or impaired use of oxygen in mitochondria, yet some are based in more complex derangements. For example, the lactic acidosis of sepsis is poorly understood but probably cannot be explained simply by tissue hypoxia, at least at the level of the whole body. Treatment of lactic acidosis involves discerning and correcting its underlying cause, ensuring adequate oxygen delivery to tissues, reducing oxygen demand through sedation and mechanical ventilation, and (in some ICUs) attempting to alkalinize the blood with IV sodium bicarbonate. Even in the face of maximal supportive therapy, lactic acidosis is associated with a mortality of 60 to 90\%.\textsuperscript{1–4}

Although the use of sodium bicarbonate for the treatment of metabolic acidosis has been debated most heavily in the past 15 years, its use was questioned as far back as 1934.\textsuperscript{5} Nevertheless, it is still considered standard therapy and recommended in many textbooks and review articles,\textsuperscript{6–8} despite the lack of relevant clinical data supporting its effectiveness. Here we review the animal and human studies that bear on this complex, yet common, clinical conundrum.

We will not address the use of sodium bicarbonate in the bicarbonate-losing metabolic acidoses, such as those caused by diarrhea or renal tubular acidosis, in which replacement of lost bicarbonate is widely accepted. Although we touch on the use of bicarbonate in diabetic ketoacidosis (DKA) and some other forms of metabolic acidosis, our discussion and conclusions largely relate to the single most common cause of severe lactic acidosis in the modern ICU, that caused by severe sepsis.\textsuperscript{4} We find little evidence that sodium bicarbonate is detrimental in these conditions, but its use fails the most basic criteria expected of any drug—efficacy.

Those who continue to advocate the use of sodium bicarbonate for lactic acidosis generally use the following chain of reasoning (explicitly or implicitly):
1. A low pH, in and of itself, is harmful (most notably by impairing cardiovascular function).
2. Sodium bicarbonate can increase the pH when infused IV.
3. Raising the pH with sodium bicarbonate improves cardiovascular function or some other relevant outcome.
4. Any adverse effects of sodium bicarbonate are outweighed by its benefits.

We address below each of these points in turn.

**IS A LOW pH BAD?**

Proteins, which underlie the function and structure of human cells, contain areas of both positive and negative charge and are thereby sensitive to the pH of the surrounding milieu. One can conceive of innumerable ways in which excess acid could impair protein function and, by extension, the function of the whole body. Yet it is overly simplistic to assume that the clinician’s window on acid-base state, the arterial blood pH, reflects accurately the pH at a (likely more important) cellular level. For example, a 50% reduction in blood flow to a tissue causes the arterial-venous PCO₂ difference to double (as long as CO₂ production and excretion remain constant) as predicted by the Fick principle. This will substantially raise the tissue PCO₂ and lower the local intracellular pH. At the same time, neither the arterial pH nor PCO₂ changes at all, both failing completely to reveal the tissue acidosis. Further clouding the value of the arterial blood pH, there may be different acid-base states in different cells of a single organ, or within different organs of a single patient. Mitochondrial pH may be even more crucial than cellular (cytoplasmic) pH, as these organelles are the site of energy production. In experiments involving isolated rat hepatocytes, the mitochondrial membrane pH gradient did not change when extracellular pH was lowered from 7.40 to 6.9.⁹

Because adults with acidosis generally also have sepsis, hypoxemia, intoxication, or hypoperfusion, discerning the physiologic effects of low pH from those of endotoxemia, hypoxemia, and so on is a challenging task. In isolated animal heart muscle preparations in which the pH of the perfusate is lowered, acidosis generally reduces contractile function,¹⁰ sometimes severely.¹¹ Human ventricular muscle excised during open-heart surgery displays only modestly reduced contractility in the face of severe acidosis.¹² The cardiac depressant effect may be caused by inorganic phosphate-mediated impairment of actin-myosin crossbridge cycling, disruption of energy production,¹¹,¹³ interference with calcium delivery to myofilaments, or decreased sensitivity of contractile proteins to calcium.¹⁴ In whole-animal preparations, the effects of acidosis are more difficult to discern, because of competing effects of acidosis on contractility, heart rate, vascular tone, and the adrenal and sympathetic systems. Various investigators have controlled heart rate, preload, and afterload, finding that acidosis caused contractility to remain constant,¹⁵ decrease marginally,¹⁶ or transiently rise and then fall.¹⁷

The increasing experience with permissive hypercapnia for patients with ARDS or status asthmaticus, in which hypercapnia and acidemia are tolerated to avoid alveolar overdistention, has changed many clinicians’ perspective about the adverse impact of acidemia. In sedated and ventilated patients with ARDS, rapid intentional hypoventilation (pH falling from 7.40 to 7.26 in 30 to 60 min) lowered systemic vascular resistance while cardiac output rose. Mean systemic arterial pressure and pulmonary vascular resistance were unchanged.¹⁸ Further, in many studies of patients undergoing permissive hypercapnia, a pH of well below 7.2 was tolerated well,¹⁸–²⁵ as it is in young patients with DKA,²⁶ children with “supercarbia,”²⁷ and those with grand mal seizures.²⁸–³⁰ The feared consequences of acidemia, projected from the experience with patients having lactic acidosis (and, usually, concomitant sepsis), failed to materialize. In normal subjects who rebreathed carbon dioxide, QT dispersion was increased, which could signal a risk of arrhythmia.²⁴ With data now available for many patients permissively hypoventilated, the systemic hemodynamic effects are quite small even as the pH falls to 7.15, with the typical patient experiencing no change or small increases in cardiac output and BP. Rhythm disturbances have not been a problem. Patients whose pH levels fall far below 7.0 are fewer in number, so firm conclusions cannot be drawn, but they similarly tolerate their acidemia. The current practice of permissive hypercapnia does not generally include an attempt to alkalinate the blood to compensate for respiratory acidosis.

Cardiac contractile response to catecholamines is also impaired by acidosis, perhaps mediated by a decline in β-receptors on the cell surface.¹³,¹¹,³² Other potentially detrimental cardiovascular effects of acidosis include reduced resuscitability from induced ventricular fibrillation, which has been shown in rats but not in dogs or pigs,³³–³⁵ impaired load tolerance of the right ventricle,³⁶ and altered renal blood flow (both increased and decreased, depending on the degree of acidemia).³⁷ Diaphragmatic contractility is reduced also by respiratory acidosis,³⁸ but apparently not by metabolic acidosis.³⁹

Paradoxically, acidosis may have protective effects in critical illness. A low pH has been shown to delay...
the onset of cell death in isolated hepatocytes exposed to anoxia\(^9\) and to chemical hypoxia.\(^{40}\) Correcting the pH took away the protective effect and accelerated cell death. In addition, acidosis during reperfusion limits myocardial infarct size.\(^{41,42}\)

In summary, although a very low pH has negative inotropic effects in isolated hearts, the whole-body response in patients is much less clearly detrimental. Although clinical shock and metabolic acidosis often coincide, the striking discordance between the clinical course and outcome of patients with (usually septic) lactic acidosis compared with those who have DKA or ventilatory failure suggests that the low pH itself does not crucially underpin the hemodynamic collapse of these ill patients. Independent of the acidemia, the lactate ion may be significant, because lactate buffered to a pH of 7.4 can cause decreased cardiac contractility in animal models.\(^{43}\)

**CAN SODIUM BICARBONATE RAISE THE pH IN VIVO?**

It seems straightforward that adding a base to acidic blood will raise the pH—the reality is more complex. First, bicarbonate is not one of the independent determinants of the blood pH. Rather, these include the difference between the total concentrations of strong cations and anions (the strong ion difference, [SID]); the total concentration of weak acids; and the Pa\(\text{CO}_2\).\(^{44}\) Administration of exogenous sodium bicarbonate increases the SID (which tends to raise the pH) because sodium is a strong cation and bicarbonate is not a strong ion at all, but at the same time it elevates the Pa\(\text{CO}_2\) (which tends to lower pH). In patients with lactic acidosis receiving mechanical ventilation, a modest infusion of sodium bicarbonate (2 mmol/kg for 15 min IV) boosted Pa\(\text{CO}_2\) from 35 to 40 mm Hg.\(^2\)

Second, bicarbonate administration may engender metabolic reactions that may themselves alter (SID); the total concentration of weak acids, or Pa\(\text{CO}_2\). For example, in animals and humans, bicarbonate infusion can augment the production of lactic acid, a strong anion,\(^{45-50}\) Mechanisms to explain this remain speculative, but include a shift in the oxyhemoglobin-saturation relationship\(^{31}\); enhanced anaerobic glycolysis, perhaps mediated by the pH-sensitive, rate-limiting enzyme phosphofructokinase; and changes in hepatic blood flow or lactate uptake.\(^{32}\)

In animal models of lactic acidosis, sodium bicarbonate does not predictably raise the arterial pH. In some studies, pH remained constant or fell.\(^{46,47}\) Most whole-animal studies, however, have shown that pH can be raised and even normalized.\(^{16,48,49,53-55}\) Most relevant to clinical practice, in two studies of patients with lactic acidosis receiving mechanical ventilation, IV infusion of sodium bicarbonate in dosages of 2 mmol/kg for 15 min or 1 mmol/kg for 1 to 2 min raised the pH only 0.14 and 0.05 units, respectively.\(^2,56\)

Yet, the body has multiple compartments separated by membranes of differing permeabilities and systems of active transport. Even when sodium bicarbonate added to the central veins reliably elevates the arterial pH, its effects on the cerebrospinal fluid and intracellular spaces may not be concordant. This could happen because carbon dioxide, produced when bicarbonate reacts with metabolic acids, diffuses readily across cell membranes and the blood-brain barrier, whereas bicarbonate cannot. Alternatively, as discussed above, bicarbonate may provoke reactions within cells, vessels, or organs that lower the local SID or raise the local PC\(\text{CO}_2\).

Sodium bicarbonate lowered cerebrospinal fluid pH in dogs with DKA,\(^{57}\) dogs being resuscitated after a ventricular fibrillation arrest,\(^{58}\) and two patients with DKA, in whom it was associated with a decrease in mental status.\(^{59}\) Intracellular pH has been measured in cells or animals using nuclear magnetic resonance spectroscopy, pH-sensitive fluorescent dyes, intramuscular electrodes, and the distribution of carbon 14-labeled dimethadione (Table 1). The results are inconsistent, with intracellular pH rising in one study,\(^{55}\) not changing in six studies,\(^{11,34,49,53,60,61}\) falling in nine studies,\(^{46,47,62-68}\) and either rising or falling depending on the buffer used in two investigations.\(^{69,70}\) In various studies, intracellular pH has been shown to fall with bicarbonate in RBCs,\(^{46}\) muscle,\(^{68}\) liver,\(^{47}\) lymphocytes,\(^{56}\) and brain.\(^{63}\) We are aware of only one human study involving determination by magnetic resonance spectroscopy of intracellular pH in the brain.\(^{65}\) When these normal volunteers were given sodium bicarbonate IV, brain pH fell significantly.

In summary, sodium bicarbonate can raise the blood pH when given IV. In contrast, this therapy fails to augment reliably the intracellular pH. Indeed, intracellular pH falls in most animal models and in most organs studied, but the effect is variable.

**DOES INCREASING THE BLOOD pH WITH SODIUM BICARBONATE HAVE ANY SALUTARY EFFECTS?**

The most direct question to pose regarding sodium bicarbonate therapy is whether it improves the problems that prompt its use. Namely, does it correct hemodynamics, “buy time” for other interventions, or improve outcome?

In isolated rat or rabbit hearts perfused with acidic solutions, bicarbonate fails to augment ventricular...
contractility.\textsuperscript{11,71} In whole animals (including various models of metabolic acidosis), the effects of bicarbonate on ventricular function are more difficult to tease out from its impact on systemic vessels. Further, one must take care not to interpret these studies too simplistically. For example, a fall in BP is not necessarily detrimental (if cardiac output rises). Nevertheless, these studies uniformly fail to reveal any hemodynamic benefit for sodium bicarbonate when compared with iso-osmolar saline solution.\textsuperscript{16,45–49,53,55,62,64,72–74} When it has been measured, cardiac output either does not change\textsuperscript{48,49,74} or falls.\textsuperscript{11,46,47} Right ventricular contractility\textsuperscript{72,74} and hepatic blood flow\textsuperscript{46,47} fall. Perhaps the most careful study of left ventricular function involved L-lactic acid infusion in anesthetized, ventilated, \(\beta\)-blocked, and atrially paced dogs. Before and after bicarbonate infusion, the left ventricular pressure-volume relationship was determined with a ventricular Millar catheter and three orthogonal pairs of ultrasonic crystals imbedded in the ventricular walls.\textsuperscript{16} Although sodium bicarbonate increased the arterial pH and did not increase lactate concentrations, mean arterial pressure fell, and cardiac output and ventricular contractility (slope of the end-systolic pressure-volume relationship) did not change. The hemodynamic effects were indistinguishable from those of saline solution.

There have been two studies of the hemodynamic impact of sodium bicarbonate in human lactic acidosis.\textsuperscript{2,56} In both studies, patients were receiving mechanical ventilation, had a mean lactate between 7 mmol/L and 8 mmol/L, and were receiving continuous infusions of vasoactive drugs (except one patient in one study). Although sodium bicarbonate raised pH and serum bicarbonate concentrations, it did not improve hemodynamics or catecholamine responsiveness. Specifically, bicarbonate was indistinguishable from saline with regard to heart rate, central venous pressure, pulmonary artery pressure, mixed venous oxyhemoglobin saturation, systemic oxygen delivery, oxygen consumption, arterial BP, pulmonary artery occlusion (wedge) pressure, and cardiac output.\textsuperscript{2,56} These findings suggest that the commonly observed hemodynamic response to bicarbonate administration in patients treated with vasoactive drug infusions may simply be one of preload augmentation (rather than enhanced catecholamine responsiveness). When the most severely acidic (pH range 6.9 to 7.2) subset of patients was analyzed separately, these negative findings persisted.\textsuperscript{2} This result does not support the practice of some physicians who withhold bicarbonate from patients with mild acidemia but feel compelled to give it to those with acidemia of greater magnitude. Indeed, if there are negative effects of bicarbonate infusion, there are reasons to expect that this subset of patients will suffer disproportionately (ie, develop more profound paradoxical intracellular acidosis).

Outcome is difficult to measure because animal models have a nearly 100% mortality and human trials have generally not been designed to detect differences in survival or other (nonhemodynamic) measures of outcome. In both prospective and retrospective studies of patients with DKA treated with or without sodium bicarbonate, there were no dif-

<table>
<thead>
<tr>
<th>Source</th>
<th>Subject</th>
<th>Acidosis</th>
<th>Method of Measuring</th>
<th>Serum pH</th>
<th>Intracellular pH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beech et al.\textsuperscript{55}</td>
<td>Rat</td>
<td>DKA, shock</td>
<td>(^{31})P NMR</td>
<td>↑</td>
<td>↑ (heart)</td>
</tr>
<tr>
<td>Blee et al.\textsuperscript{49}</td>
<td>Dog</td>
<td>Hypoxic lactic</td>
<td>(^{31})P NMR</td>
<td>⇔</td>
<td>⇔ (heart)</td>
</tr>
<tr>
<td>Beech et al.\textsuperscript{53}</td>
<td>Rat</td>
<td>Hypotensive lactic</td>
<td>C2 NMR</td>
<td>↑</td>
<td>⇔ (muscle)</td>
</tr>
<tr>
<td>Bollerta et al.\textsuperscript{60}</td>
<td>Rat</td>
<td>Septic (LPS)</td>
<td>(^{31})P NMR</td>
<td>↑</td>
<td>⇔ (muscle)</td>
</tr>
<tr>
<td>Shapiro\textsuperscript{11}</td>
<td>Rat heart</td>
<td>Acidic perfusate</td>
<td>(^{31})P NMR</td>
<td>↑</td>
<td>⇔ (heart)</td>
</tr>
<tr>
<td>Thompson et al.\textsuperscript{61}</td>
<td>Rat</td>
<td>None</td>
<td>(^{31})P NMR</td>
<td>↑</td>
<td>⇔ or ↓ depending on route (IV or IP)</td>
</tr>
<tr>
<td>Kette et al.\textsuperscript{34}</td>
<td>Pig</td>
<td>Cardiac arrest</td>
<td>Electrode</td>
<td>↑</td>
<td>⇔ (heart)</td>
</tr>
<tr>
<td>Arieff et al.\textsuperscript{46}</td>
<td>Dog</td>
<td>Phenformin lactic</td>
<td>(^{14})C DMO</td>
<td>⇔</td>
<td>↓ (liver, RBC)</td>
</tr>
<tr>
<td>Graf et al.\textsuperscript{47}</td>
<td>Dog</td>
<td>Hypoxic lactic</td>
<td>(^{14})C DMO</td>
<td>↓</td>
<td>↓ (liver)</td>
</tr>
<tr>
<td>Bersin and Arieff\textsuperscript{62}</td>
<td>Dog</td>
<td>Hypoxic lactic</td>
<td>(^{14})C DMO</td>
<td>↓</td>
<td>↓ (liver)</td>
</tr>
<tr>
<td>Shapiro et al.\textsuperscript{63}</td>
<td>Rat</td>
<td>NH(_4)Cl, hypercapnic</td>
<td>(^{31})P NMR</td>
<td>↑</td>
<td>↓ (brain)</td>
</tr>
<tr>
<td>Shapiro et al.\textsuperscript{64}</td>
<td>Rat</td>
<td>NH(_4)Cl</td>
<td>(^{31})P NMR</td>
<td>↑</td>
<td>↓ (liver)</td>
</tr>
<tr>
<td>Arieff et al.\textsuperscript{65}</td>
<td>Animal</td>
<td>Phenformin lactic</td>
<td>Not stated</td>
<td>↑</td>
<td>↓ (liver and muscle)</td>
</tr>
<tr>
<td>Nakashima et al.\textsuperscript{65}</td>
<td>Human</td>
<td>None</td>
<td>(^{31})P NMR</td>
<td>↑</td>
<td>↓ (brain)</td>
</tr>
<tr>
<td>Bjerrenroth et al.\textsuperscript{66}</td>
<td>Lymphocytes</td>
<td>Acidic buffer</td>
<td>Fluorescent dye</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>Ritter et al.\textsuperscript{67}</td>
<td>Platelets</td>
<td>Acidic buffer</td>
<td>Fluorescent dye</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>Levrant et al.\textsuperscript{70}</td>
<td>Rat hepatocytes</td>
<td>Acidic buffer</td>
<td>Fluorescent dye</td>
<td>↑ or ↓ depending on buffer</td>
<td>↓</td>
</tr>
<tr>
<td>Goldsmith et al.\textsuperscript{69}</td>
<td>Leukocytes</td>
<td>Acidic buffer</td>
<td>Fluorescent dye</td>
<td>↑ or ↓ depending on buffer</td>
<td>↓</td>
</tr>
</tbody>
</table>

\(\text{NH}_4\text{Cl} = \text{ammonium chloride; NMR = nuclear magnetic resonance; DMO = dimethyloxazolidine; IP = intraperitoneal; LPS = lipopolysaccharide; ↑ = increase; ↓ = decrease; ⇔ = no change.}\)
ferences in the neurologic status, incidence of hypo-
kalemia or hypoglycemia, or rate of correction of
acidemia, but there was a suggestion of delayed
clearance of ketones and lactate in patients given
bicarbonate. Dichloroacetate (DCA) infusion,
which, like sodium bicarbonate infusion, effectively
raises serum pH in critically ill patients with lactic
acidosis (but lowers lactate concentrations), also has
no apparent hemodynamic benefit and does not
improve survival.

The only study that has shown any positive effect
on outcome is in the setting of canine ventricular
fibrillation. Dogs resuscitated from prolonged ar-
rest who were given bicarbonate had improved
return of the circulation, less neurologic deficit, and
greater survival to 24 h. On the other hand, several
other studies in both humans and animals do not
support these data. A study in dogs showed no effect
of respiratory or metabolic acidosis on defibrillation
threshold. Sodium bicarbonate had no detectable
impact on myocardial cell pH or resuscitability from
ventricular fibrillation in pigs in one study and
worsened coronary perfusion pressure and resuscit-
ability in yet another. Its use was associated with
poorer outcomes in a retrospective study of human
cardiopulmonary arrest.

In summary, no controlled study has shown im-
proved hemodynamics attributable to sodium bicar-
bonate infusion, regardless of the effect on pH, and
many show worsening of some hemodynamic vari-
able. It is significant that such negative findings
include two studies in critically ill humans receiving
infused catecholamines, the subset of patients who
might be expected to benefit most dramatically.

**Does Sodium Bicarbonate Have Negative Side Effects?**

The most obvious side effects of sodium bicarbon-
ate are the fluid and sodium load. This can cause
hypervolemia, hyperosmolarity, and hypernatremia.
Sodium bicarbonate given as a rapid IV bolus
can cause a transient fall in mean arterial pressure
and a transient rise in intracranial pressure that is
probably related to its hypertonicity, and this is
alleviated when given as a slow IV infusion. Sodium
bicarbonate has been shown in three studies to lower
PaO₂ from 5 to 15 mm Hg in both aciemic animals
and nonacemic patients with congestive heart fail-
ure. The mechanism for this is unclear, but the
authors speculated that there might be worsening of
intrapulmonary shunt.

When normal human volunteers were made aci-
demic with acetazolamide and then corrected with
sodium bicarbonate, the acute correction of the pH
caus ed increased hemoglobin affinity for oxygen that
worsened oxygen delivery. This effect lasted about
8 h. This was thought to be caused by the imme-
diate nature of the Bohr effect and the delayed
nature of the 2,3-diphosphoglycerate effect on he-
moglobin-oxygen affinity.

Lactate concentrations increased with sodium bi-
carbonate infusion (compared with control subjects)
in animal studies of hypoxic lactic acidosis, phenformin-induced lactic acidosis, hemorrhagic shock, and DKA. This finding has also been reported in cases of chronic lactic acidosis associated with malignancies. It is possible that lactate rises in these settings because of impaired oxygen delivery to tissues. Even if enhanced lactate production does not signal cellular hypoxia, bicarbonate-induced hyper-
lactatemia may be detrimental inasmuch as lactate
itself has potentially detrimental actions, as discussed
earlier.

Serum ionized calcium concentration is reduced
by sodium bicarbonate infusion. In a randomized,
controlled study of ICU patients with lactic acidosis,
sodium bicarbonate lowered ionized calcium from
0.95 to 0.87 mmol/L. In an animal study of cardiac
arrest, sodium bicarbonate decreased ionized cal-
cium, although this had no apparent detrimental
effects. Because left ventricular contractility has
been shown to vary directly with ionized calcium
concentration, any beneficial effects of pH correc-
tion may be masked by hypocalcemic ventricular
depression.

A single study in patients with lactic acidosis
treated with sodium bicarbonate failed to reveal any
significant changes in venous lactate concentration,
hemoglobin affinity for oxygen, total body oxygen
consumption, oxygen extraction ratio, transcutane-
ous oxygen pressure, serum sodium concentration,
or osmolality. However, the dose of bicarbonate (1
mmol/kg) was small. Another study of three patients
treated with sodium bicarbonate (mean dose, 90
mEq) during cardiac arrest revealed a rise in osmo-
lality from 308 to 343 mosm/kg.

In summary, many potentially detrimental effects
of bicarbonate administration have been identified,
but their clinical relevance has not been established.

**Other Alkalizing Therapies: Carbicarb, Dichloroacetate, Tris-Hydroxymethyl Aminomethane, and Dialysis**

Carbicarb is an equimolar mixture of sodium carbo-
inate and sodium bicarbonate. Compared with
sodium bicarbonate, Carbicarb raises the SID
(thereby the pH) far more and boosts the
PCO₂ far less when given IV to animals with
metabolic acidosis. To the extent that the failure of sodium bicarbonate to effect hemodynamic improvement is caused by the generation of carbon dioxide, Carbicarb might be superior. Carbicarb more consistently increases intracellular pH, and although it improved hemodynamics in two studies, it did not in three others.

DCA is a compound that probably works by stimulating the pyruvate dehydrogenase complex, the rate-limiting enzyme that regulates the entry of pyruvate into the tricarboxylic acid cycle, thus promoting the clearance of accumulated lactate. In addition, DCA increases myocardial glucose utilization and contractility. Although several animal and clinical trials showed that DCA could raise pH and bicarbonate concentration while lowering lactate concentrations, with little apparent toxicity, a large, multicenter, placebo-controlled trial in patients with lactic acidosis failed to confirm improved hemodynamics or outcome. This drug is not available commercially. Tris-hydroxymethyl aminomethane is a weak alkali that penetrates cells easily. Its potential to raise blood and intracellular pH without producing carbon dioxide has been confirmed in animal models of metabolic acidosis. Tris-hydroxymethyl aminomethane also improved myocardial contraction and relaxation in an isolated rabbit heart preparation. Although tris-hydroxymethyl aminomethane is commercially available, complications of hyperkalemia, hypoglycemia, extravasation-related necrosis, and neonatal hepatic necrosis are likely to limit its use.

There have been many case studies that report the use of dialysis to control the volume and sodium loads that accompany sodium bicarbonate infusion. In most of these reports, sodium bicarbonate alone did not improve the pH or lactate concentrations, but bicarbonate-buffered peritoneal dialysis did. Perhaps importantly, peritoneal dialysis was very effective at removing lactate. The returned dialysate contained between 2.6 mEq/L and 14 mEq/L of lactate in one study, and the calculated lactate clearance by peritoneal dialysis averaged 21 mL/min in another. The impact of bicarbonate infusion plus dialysis on cardiovascular function and outcome has not been studied systematically, nor has the relevance of the bicarbonate component of this potential treatment been examined.

**Conclusion**

Sodium bicarbonate is clearly effective in raising the arterial pH in critically ill patients with lactic acidosis. The impact on intracellular pH is unknown in such patients, but extrapolation from extensive animal studies suggests that it is negative. Despite the correction of arterial acidemia, sodium bicarbonate, like DCA, has no favorable cardiovascular effects, even for patients with severe acidemia and receiving continuous infusions of catecholamines. Although hemodynamic improvement is not the only mechanism by which bicarbonate might be beneficial, animal studies have failed to yield alternatives. Even theoretical arguments in favor of sodium bicarbonate administration rely on a naïve representation of acid-base physiology, ignoring the complex compartmentalization of pH, the second-level effects of bicarbonate infusion, the impact of carbon dioxide generation, or the negative consequences of hyperlactatemia. We believe most clinicians who continue to use bicarbonate for patients with severe lactic acidosis do so largely because of their inclination to action: How can I “fail” to give bicarbonate when no alternative therapy is available and the mortality of this condition is so high?

The oft-cited rationale for bicarbonate use, that it might ameliorate the hemodynamic depression of metabolic acidemia, has been disproven convincingly. Any future role for bicarbonate in these patients depends on the formulation of new hypotheses of efficacy followed by animal and clinical studies to seek to confirm any proposed benefit. Given the current lack of evidence supporting its use, we cannot condone bicarbonate administration for patients with lactic acidosis. We extend this to those with pH < 7.2 on vasoactive drugs, inasmuch as bicarbonate has no measurable beneficial effects even in these sickest patients. Indeed, we do not give or advise bicarbonate infusion regardless of the pH.

**References**

9. Bonventre JV, Cheung JY. Effects of metabolic acidosis on...
viability of cells exposed to anoxia. Am J Physiol 1985; 249:C149–C159
14 Orchard CH, Kentish JC. Effects of pH change on the contractile function of cardiac muscle. Am J Physiol 1990; 258:C967–C981
19 Feihl F, Perret C. Permissive hypercapnia: how permissive should we be? Am J Respir Crit Care Med 1994; 150:1722–1737
51 Bellingham AJ, Detter JC, Lenfant C. Regulatory mecha-
67 Ritter JM, Doktor HS, Benjamin N. Paradoxical effect of bicarbonate on cytoplasmic pH. Lancet 1990; 335:1243–1246
80 Kette F, Weil MH, Ganzuri RJ. Buffer solutions may compromise cardiac resuscitation by reducing coronary perfusion pressure. JAMA 1991; 266:2121–2126
87 Stacpoole PW. The pharmacology of dichloroacetate. Metabolism 1989; 38:1124–1144